Vanda Pharmaceuticals Inc. focuses on developing innovative therapies aimed at addressing unmet medical needs, particularly in the fields of sleep disorders and psychiatric conditions. One of their key products, HETLIOZ® (tasimelteon), is specifically designed for the treatment of Non-24-Hour Sleep-Wake Disorder, a condition that affects individuals who are blind or have difficulty regulating their circadian rhythms. The company also offers Fanapt® (iloperidone), an antipsychotic medication used to treat schizophrenia, and PONVORY® (ponesimod), which is aimed at treating multiple sclerosis. These products reflect Vanda's commitment to uncovering breakthroughs in therapeutic areas that significantly impact patients' quality of life.

In addition to their product offerings, Vanda Pharmaceuticals emphasizes the importance of clinical development and research in their pipeline. The company actively engages in expanding access to their medications through programs like HETLIOZAccess®, which provides treatment options for patients with Non-24. Vanda's approach combines rigorous scientific research with a focus on patient needs, ensuring that their innovations are not only effective but also accessible to those who require them. This dedication to advancing medical science underscores Vanda's mission to enhance the pursuit of happiness for individuals facing challenging health conditions.

United States

Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.

Central Nervous System (CNS)

Digestive System Diseases

Hematologic Diseases

Psychological Diseases

Skin Diseases

Vanda Pharmaceuticals Inc.

Bipolar depression

Bipolar disease

Mental health

The mechanism of action of FANAPT, as with other drugs having efficacy in schizophrenia, is unknown. However it is proposed that the efficacy of FANAPT is mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5-HT2) antagonisms (<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf">learn more</a> pg.19)

Fanapt® (iloperidone) 

Non-24-Hour Sleep-Wake Disorder

The precise mechanism by which tasimelteon exerts its therapeutic effect in patients with Non- 24 is not known. Tasimelteon is an agonist at melatonin MT1 and MT2 receptors. These receptors are thought to be involved in the control of circadian rhythms (<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205677s000lbledt.pdf">Learn more</a> pg.6)

HETLIOZ® (tasimelteon)

Schizophrenia

Fanapt® (iloperidone)

Smith-Magenis Syndrome

The precise mechanism by which tasimelteon exerts its therapeutic effect in patients with Non- 24 is not known. Tasimelteon is an agonist at melatonin MT1 and MT2 receptors. These receptors are thought to be involved in the control of circadian rhythms (<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205677s000lbledt.pdf">learn more</a> pg 6).&nbsp;

Multiple sclerosis

PONVORY® is a once-daily oral selective sphingosine-1-phosphate receptor 1 modulator, approved by the FDA and Health Canada to treat adults with relapsing forms of multiple sclerosis, and is a potential therapeutic candidate for the treatment of a diverse group of inflammatory/autoimmune disorders ranging from psoriasis to ulcerative colitis.

PONVORY® (ponesimod)

Bysanti™ (milsaperidone)

Gastroparesis

Tradipitant is an orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor; NK1R; NK-1R) antagonist with potential anti-emetic, anti-pruritic and anti-inflammatory activities. Upon oral administration, tradipitant competitively binds to and blocks the activity of the NK1R in the central nervous system (CNS), thereby inhibiting the binding of the endogenous ligand and neuropeptide, <a href="https://pubchem.ncbi.nlm.nih.gov/compound/substance%20P" rel="follow">substance P</a> (SP; neurokinin-1; NK1). This inhibits SP/NK1-mediated signal transduction and may prevent both SP-induced emesis and pruritis. In addition, inhibition of SP/NK1R signaling also reduces neurogenic inflammation which is triggered by the release of neuropeptides, such as <a href="https://pubchem.ncbi.nlm.nih.gov/compound/substance%20P" rel="follow">substance P</a>, from nerve cells. NK1R is a G protein-coupled receptor (GPCR) that preferentially binds to SP, a neuropeptide secreted by neuronal cells and inflammatory cells (<a href="https://pubchem.ncbi.nlm.nih.gov/compound/Tradipitant">Learn more</a> - National Library of Medicine)

Tradipitant

Jet Lag

The precise mechanism by which tasimelteon exerts its therapeutic effect in patients with Non- 24 is not known. Tasimelteon is an agonist at melatonin MT1 and MT2 receptors. These receptors are thought to be involved in the control of circadian rhythms (<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205677s000lbledt.pdf" rel="noopener" target="_blank">learn more</a> pg 6).

Motion sickness

Tradipitant is an orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor; NK1R; NK-1R) antagonist with potential anti-emetic, anti-pruritic and anti-inflammatory activities. Upon oral administration, tradipitant competitively binds to and blocks the activity of the NK1R in the central nervous system (CNS), thereby inhibiting the binding of the endogenous ligand and neuropeptide, <a href="https://pubchem.ncbi.nlm.nih.gov/compound/substance%20P" rel="noopener" target="_blank">substance P</a> (SP; neurokinin-1; NK1). This inhibits SP/NK1-mediated signal transduction and may prevent both SP-induced emesis and pruritis. In addition, inhibition of SP/NK1R signaling also reduces neurogenic inflammation which is triggered by the release of neuropeptides, such as <a href="https://pubchem.ncbi.nlm.nih.gov/compound/substance%20P" rel="noopener" target="_blank">substance P</a>, from nerve cells. NK1R is a G protein-coupled receptor (GPCR) that preferentially binds to SP, a neuropeptide secreted by neuronal cells and inflammatory cells. (<a href="https://pubchem.ncbi.nlm.nih.gov/compound/Tradipitant" rel="noopener" target="_blank">source</a> - National Library of Medicine (National Institute of Health))

Insomnia

Social Anxiety Disorder

Alpha-7 nicotinic acetylcholine receptor partial agonist

VQW-765

Major depressive disorder

Dry eye disease

VSJ-110

Charcot-Marie-Tooth disease, axonal, type 2S

Neuropathy

VCA-894A 

Fungal infections

Onychomycosis

Acetylation and deacetylation of histones play an important role in transcription regulation of eukaryotic cells (<a href="https://www.nature.com/articles/1210620#ref-CR57" title="Lehrmann H, Pritchard LL, Harel-Bellan A . (2002). Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 86: 41–65.">Lehrmann et al., 2002</a>; <a href="https://www.nature.com/articles/1210620#ref-CR62" title="Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R et al. (2005). Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 25: 261–309.">Mai et al., 2005</a>). The acetylation status of histones and non-histone proteins is determined by histone deacetylases (HDACs) and histone acetyl-transferases (HATs). HATs add acetyl groups to lysine residues, while HDACs remove the acetyl groups. In general, acetylation of histone promotes a more relaxed chromatin structure, allowing transcriptional activation. HDACs can act as transcription repressors, due to histone deacetylation, and consequently promote chromatin condensation. HDAC inhibitors (HDACi) selectively alter gene transcription, in part, by chromatin remodeling and by changes in the structure of proteins in transcription factor complexes (<a href="https://www.nature.com/articles/1210620#ref-CR37" title="Gui CY, Ngo L, Xu WS, Richon VM, Marks PA . (2004). Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101: 1241–1246.">Gui et al., 2004</a>). Further, the HDACs have many non-histone proteins substrates such as hormone receptors, chaperone proteins and cytoskeleton proteins, which regulate cell proliferation and cell death (<a href="https://www.nature.com/articles/1210620#Tab1">Table 1</a>). Thus, HDACi-induced transformed cell death involves transcription-dependent and transcription-independent mechanisms (<a href="http://Xu, W. S., Parmigiani, R. B., &amp; Marks, P. A. (2007). Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene, 26(37), 5541-5552.">Learn more</a>).

Trichostatin A (VTR-297) 

Atopic dermatitis

Atopic pruritus

Leukemia

Lymphoma

Multiple myeloma

Trichostatin A (VTR-297)

COVID-19

Tradipitant is an orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor; NK1R; NK-1R) antagonist with potential anti-emetic, anti-pruritic and anti-inflammatory activities. Upon oral administration, tradipitant competitively binds to and blocks the activity of the NK1R in the central nervous system (CNS), thereby inhibiting the binding of the endogenous ligand and neuropeptide, <a href="https://pubchem.ncbi.nlm.nih.gov/compound/substance%20P" rel="follow">substance P</a> (SP; neurokinin-1; NK1). This inhibits SP/NK1-mediated signal transduction and may prevent both SP-induced emesis and pruritis. In addition, inhibition of SP/NK1R signaling also reduces neurogenic inflammation which is triggered by the release of neuropeptides, such as <a href="https://pubchem.ncbi.nlm.nih.gov/compound/substance%20P" rel="follow">substance P</a>, from nerve cells. NK1R is a G protein-coupled receptor (GPCR) that preferentially binds to SP, a neuropeptide secreted by neuronal cells and inflammatory cells. (<a href="https://pubchem.ncbi.nlm.nih.gov/compound/Tradipitant">source</a> - National Library of Medicine (National Institute of Health))

Vanda Pharmaceuticals Inc.

Company Details